Screener
Janux Therapeutics JANX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Assets | June 30,2026 / (unaudited) | December 31,2025 |
|---|---|---|
| Accrued expenses | 19,513 | 17,633 |
| Current portion of deferred revenue | 35,070 | — |
| Current portion of operating lease liabilities | 2,552 | 2,393 |
| Total current liabilities | 60,152 | 24,997 |
| Deferred revenue, net of current portion | 1,079 | — |
| Operating lease liabilities, net of current portion | 18,438 | 19,746 |
| Total liabilities | 79,669 | 44,743 |
| Commitments and contingencies (Note 3) |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's total current liabilities?
- Janux Therapeutics (JANX) reported total current liabilities of $60.15M in Q2 2026.
- How has Janux Therapeutics's total current liabilities changed year-over-year?
- Janux Therapeutics's total current liabilities increased by 181.4% year-over-year, from $21.38M to $60.15M.
- What is the long-term trend for Janux Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Janux Therapeutics's total current liabilities has grown at a 51.0% compound annual growth rate (CAGR), from $3.18M to $25M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Janux Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude